Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

May 30, 2027

Study Completion Date

September 7, 2027

Conditions
GlioblastomaDiffuse Glioma
Interventions
DRUG

NMS-03305293

Route of administration: Oral

DRUG

Temozolomide

"Route of administration: Oral~Commercially available temozolomide"

Trial Locations (18)

3015

Erasmus Medical Center, Rotterdam

8091

University Hospital Zurich, Zurich

10065

Memorial Sloan-Kettering Cancer Center, New York

20089

Istituto Clinico Humanitas, Rozzano

20133

IRCCS Istituto Neurologico Carlo Besta, Milan

22908

University of Virginia Health System, Charlottesville

32224

Mayo Clinic Florida, Jacksonville

35128

Istituto Oncologico Veneto - IRCCS, Padua

40139

IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna

55905

Mayo Clinic Cancer Center, Rochester

75390

UT Southwestern Medical Center, Dallas

77030

The University of Texas MD Anderson Cancer Center, Houston

84112

University of Utah, University Hospital, Salt Lake City

85054

Mayo Clinic Hospital - Phoenix, Phoenix

92868

University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange

98122

Swedish Medical Center - First Hill Campus, Seattle

02215

Dana-Farber Cancer Institute, Boston

00935

PanOncology Trials (Pan American Center for Oncology Trials, LLC), Rio Piedras

Sponsors
All Listed Sponsors
lead

Nerviano Medical Sciences

INDUSTRY

NCT04910022 - Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter